Dengue infection has been becoming a serious public health problem in many countries with a dramatic increase globally. There are approximately 2.5 billion people at risk of dengue in over 100 countries. It is estimated that over 20,000 deaths occur every year due to this disease. Dengue hemorrhagic fever (DHF) is the severe form of dengue infection, which is characterized by plasma leakage possibly inducing hypovolemic shock, known as dengue shock syndrome (DSS). Some patients infected by dengue virus develop dengue fever (DF), some develop DHF and about 20-30% of them, who suffer from DHF, develop shock. At present, there is no approved dengue vaccine nor antiviral drug, although some potential solutions are currently being studied. Early treatment, vector control, and educational program are the only methods to reduce global disease burden and mortality. Therefore, it is important to understand the pathogenesis of dengue infection in order to find an appropriate management.
Proteomic Profile of Circulating Immune Complexes in Dengue Infected Patients- Kaname Ohyama
OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals. Journal of Tropical Diseases & Public Heath is one of the top journals which publish quality articles, findings dealing with tropical diseases related to human health.
Last date updated on June, 2014